PL2705143T3 - Technologia indukowanych białkiem komórek pluripotencjalnych, jej zastosowania - Google Patents
Technologia indukowanych białkiem komórek pluripotencjalnych, jej zastosowaniaInfo
- Publication number
- PL2705143T3 PL2705143T3 PL12779306T PL12779306T PL2705143T3 PL 2705143 T3 PL2705143 T3 PL 2705143T3 PL 12779306 T PL12779306 T PL 12779306T PL 12779306 T PL12779306 T PL 12779306T PL 2705143 T3 PL2705143 T3 PL 2705143T3
- Authority
- PL
- Poland
- Prior art keywords
- protein
- induced pluripotent
- pluripotent cell
- technology uses
- cell technology
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/605—Nanog
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161481273P | 2011-05-02 | 2011-05-02 | |
EP12779306.5A EP2705143B1 (en) | 2011-05-02 | 2012-05-02 | A protein-induced pluripotent cell technology uses thereof |
PCT/US2012/036051 WO2012151234A2 (en) | 2011-05-02 | 2012-05-02 | A protein-induced pluripotent cell technology uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2705143T3 true PL2705143T3 (pl) | 2021-07-19 |
Family
ID=47108197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12779306T PL2705143T3 (pl) | 2011-05-02 | 2012-05-02 | Technologia indukowanych białkiem komórek pluripotencjalnych, jej zastosowania |
Country Status (8)
Country | Link |
---|---|
US (4) | US9816076B2 (pl) |
EP (2) | EP2705143B1 (pl) |
CN (2) | CN103826459B (pl) |
DK (1) | DK2705143T3 (pl) |
ES (2) | ES2957478T3 (pl) |
PL (1) | PL2705143T3 (pl) |
PT (1) | PT2705143T (pl) |
WO (1) | WO2012151234A2 (pl) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
DK2705143T3 (da) | 2011-05-02 | 2021-05-10 | Univ Wayne State | Protein-induceret pluripotent celleteknologi og anvendelse deraf |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
DK3060237T3 (da) * | 2013-10-25 | 2021-10-25 | Univ Wayne State | Modificeret omprogrammeringsprotein til anvendelse i behandling af cancer |
KR101781693B1 (ko) * | 2015-09-24 | 2017-09-26 | 서울대학교병원 | 심장내막 유래 성체줄기세포로부터 제조된 유도만능 줄기세포의 심혈관계 세포로의 분화방법 및 이의 용도 |
GB201909975D0 (en) * | 2019-07-11 | 2019-08-28 | Babraham Inst | Novel reprogramming method |
WO2021149823A1 (ja) * | 2020-01-24 | 2021-07-29 | アイ ピース, インコーポレイテッド | 因子を導入された細胞の培養方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
DE60230147D1 (de) | 2001-07-06 | 2009-01-15 | Merck Patent Gmbh | Verfahren zur überwachung und modulierung von proteinfaltung |
ES2290337T3 (es) | 2001-11-30 | 2008-02-16 | Laboratoires Serono Sa | Metodos para aumentar los niveles de expresion del receptor tnf humano. |
US20030134352A1 (en) | 2002-01-04 | 2003-07-17 | Freimuth Paul I. | Facilitating protein folding and solubility by use of peptide extensions |
EP1468105A2 (en) | 2002-01-07 | 2004-10-20 | European Molecular Biology Laboratory | Recombinant protein expression |
WO2005026196A2 (en) | 2003-09-12 | 2005-03-24 | Novexin Limited | Methods for folding proteins and reducing protein aggregation |
SG10201607710UA (en) * | 2008-03-17 | 2016-11-29 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
US8722348B2 (en) * | 2008-05-28 | 2014-05-13 | Wayne State University | Method and composition for a protein transduction technology and its applications |
CA2695590C (en) | 2008-06-27 | 2018-01-09 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2010115052A2 (en) * | 2009-04-03 | 2010-10-07 | The Mclean Hospital Corporation | Induced pluripotent stem cells |
US20120115225A1 (en) * | 2009-04-23 | 2012-05-10 | Xu C W | Reprogramming of somatic cells with purified proteins |
EP2253700A1 (en) * | 2009-05-13 | 2010-11-24 | Helmholtz-Zentrum für Infektionsforschung GmbH | A method for producing test systems from donors suffering from adverse effects of medicaments and /or medical treatments, and uses of said systems |
CN101993495B (zh) * | 2009-08-12 | 2013-07-24 | 上海近岸科技有限公司 | 一种蛋白质混合物及其制备方法 |
US8716020B2 (en) * | 2009-11-13 | 2014-05-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Reprogrammation of eukaryotic cells with engineered microvesicles |
CN101906419A (zh) * | 2010-07-29 | 2010-12-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 可用于高效制备诱导性多能干细胞的小分子化合物和方法 |
DK2705143T3 (da) * | 2011-05-02 | 2021-05-10 | Univ Wayne State | Protein-induceret pluripotent celleteknologi og anvendelse deraf |
-
2012
- 2012-05-02 DK DK12779306.5T patent/DK2705143T3/da active
- 2012-05-02 EP EP12779306.5A patent/EP2705143B1/en active Active
- 2012-05-02 WO PCT/US2012/036051 patent/WO2012151234A2/en active Application Filing
- 2012-05-02 PL PL12779306T patent/PL2705143T3/pl unknown
- 2012-05-02 CN CN201280032517.8A patent/CN103826459B/zh active Active
- 2012-05-02 CN CN201710255470.6A patent/CN107012118A/zh active Pending
- 2012-05-02 US US14/113,522 patent/US9816076B2/en active Active
- 2012-05-02 PT PT127793065T patent/PT2705143T/pt unknown
- 2012-05-02 ES ES20197841T patent/ES2957478T3/es active Active
- 2012-05-02 ES ES12779306T patent/ES2866411T3/es active Active
- 2012-05-02 EP EP20197841.8A patent/EP3777538B1/en active Active
-
2017
- 2017-11-09 US US15/808,205 patent/US10221397B2/en active Active
-
2019
- 2019-02-08 US US16/271,150 patent/US10640751B2/en active Active
-
2020
- 2020-04-15 US US16/849,515 patent/US11685903B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180127725A1 (en) | 2018-05-10 |
WO2012151234A3 (en) | 2014-02-20 |
US20190161739A1 (en) | 2019-05-30 |
EP2705143B1 (en) | 2021-02-17 |
US10640751B2 (en) | 2020-05-05 |
EP2705143A2 (en) | 2014-03-12 |
EP3777538A1 (en) | 2021-02-17 |
EP2705143A4 (en) | 2015-12-16 |
US20140242695A1 (en) | 2014-08-28 |
CN103826459A (zh) | 2014-05-28 |
US10221397B2 (en) | 2019-03-05 |
US20200291362A1 (en) | 2020-09-17 |
ES2866411T3 (es) | 2021-10-19 |
ES2957478T3 (es) | 2024-01-19 |
CN107012118A (zh) | 2017-08-04 |
US9816076B2 (en) | 2017-11-14 |
PT2705143T (pt) | 2021-04-07 |
DK2705143T3 (da) | 2021-05-10 |
CN103826459B (zh) | 2017-05-10 |
US11685903B2 (en) | 2023-06-27 |
WO2012151234A2 (en) | 2012-11-08 |
EP3777538B1 (en) | 2023-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2705143T3 (pl) | Technologia indukowanych białkiem komórek pluripotencjalnych, jej zastosowania | |
IL232106A0 (en) | Multi-cell battery composition | |
EP2631962A4 (en) | THIN BATTERY | |
SG10201601434RA (en) | Cell Culture System | |
EP2779269A4 (en) | BATTERY CELL WITH NOVEL CONSTRUCTION | |
EP2664017A4 (en) | STACK OF FLOW CELLS | |
EP2782184A4 (en) | BATTERY | |
SG10201605543SA (en) | A redox flow battery system | |
EP2717377A4 (en) | DRUMS | |
EP2784869A4 (en) | BLOCK OF ELEMENTS | |
HK1192498A1 (en) | Serviceable bioreactor | |
EP2729561A4 (en) | CELL CULTURE METHOD | |
ZA201505146B (en) | A solar cell | |
EP2686897A4 (en) | BATTERY | |
EP2738836A4 (en) | RECTANGULAR BATTERY | |
EP2685526A4 (en) | CELL CONNECTION ARRANGEMENT | |
SG11201500417PA (en) | Cell culture | |
PL2814945T3 (pl) | Komórki o zmniejszonej aktywności PPGPPazy | |
EP2704285A4 (en) | BATTERY PACK | |
EP2924787A4 (en) | SINGLE CELL OF FUEL CELL | |
EP2725637A4 (en) | BATTERY | |
EP2800229A4 (en) | BATTERY SYSTEM | |
EP2690698A4 (en) | BATTERY | |
EP2709203A4 (en) | CELL SYSTEM | |
GB201223495D0 (en) | A Bioreactor |